Summary
Boston Scientific Corporation (BSX) reported solid revenue growth in the second quarter and first half of 2017, demonstrating a return to profitability compared to the prior year's loss. Net sales increased by 6% in Q2 and 8% for the first half, driven by strong performance across key segments including Cardiovascular, MedSurg, and Neuromodulation. The company successfully integrated the acquisition of Symetis SA and expanded its structural heart offerings, while also managing a substantial portfolio of ongoing litigation and restructuring efforts. Despite significant litigation-related charges, particularly for transvaginal surgical mesh cases, the company achieved net income of $146 million in Q2 2017 and $436 million for the first half, a significant improvement from the net loss experienced in the comparable periods of 2016. Management highlighted adjusted net income, which excludes various charges and credits, as a measure of ongoing operational performance, showing strong profitability. The company maintained a solid debt maturity profile and adequate liquidity to support its operations.
Financial Highlights
50 data points| Revenue | $2.26B |
| Cost of Revenue | $632.00M |
| Gross Profit | $1.63B |
| SG&A Expenses | $815.00M |
| Operating Expenses | $1.40B |
| Operating Income | $225.00M |
| Interest Expense | $58.00M |
| Net Income | $146.00M |
| EPS (Basic) | $0.11 |
| EPS (Diluted) | $0.11 |
| Shares Outstanding (Basic) | 1.37B |
| Shares Outstanding (Diluted) | 1.39B |
Key Highlights
- 1Net sales increased by 6% to $2.257 billion in Q2 2017 and by 8% to $4.418 billion in the first half of 2017, compared to the prior year periods.
- 2The company returned to profitability, reporting net income of $146 million ($0.11 per share) in Q2 2017 and $436 million ($0.31 per share) for the first half, a significant improvement from losses in 2016.
- 3Acquisition of Symetis SA for approximately $430 million completed in May 2017, strengthening the structural heart business.
- 4Significant litigation-related charges totaling $205 million in Q2 2017 and $208 million for the first half, primarily related to transvaginal surgical mesh product liability cases.
- 5Gross profit margin improved to 72.0% in Q2 2017 and 71.0% for the first half, driven by manufacturing cost reductions and favorable product mix.
- 6Operating cash flow was $299 million for the first half of 2017, though lower than the $537 million in the prior year, impacted by working capital changes and litigation payments.
- 7The company maintained a robust debt structure with $5.835 billion in total debt as of June 30, 2017, and access to significant credit facilities, with no borrowings under its $2 billion revolving credit facility.